Everything below concerns angiogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
== Ecology == As most endoliths are autotrophs, they can generate organic compounds essential for their survival on their own from inorganic matter. Some endoliths have specialized in feeding on their autotroph relatives. The micro-biotope where these different endolithic species live together has been called a subsurface lithoautotrophic microbial ecosystem (SLiME), or endolithic systems within the subterranean lithic biome. Endolithic systems are still at an early stage of exploration. In some cases its biota can support simple invertebrates, most organisms are unicellular. Near-surface layers of rock may contain blue-green algae but most energy comes from chemical synthesis of minerals. The limited supply of energy limits the rates of growth and reproduction. In deeper rock layers microbes are exposed to high pressures and temperatures.
This is a list of Nobel laureates who are Poles (ethnic) or Polish (citizenship). The Nobel Prize is a set of annual international awards bestowed on "those who conferred the greatest benefit on humankind", first instituted in 1901. Since 1903, there have been nineteen Poles who were awarded twenty Nobel Prizes. Poles have been the recipients of all Nobel prize categories: Physics, Chemistry, Physiology or Medicine, Literature, Peace and Economics.
The Greater Poland uprising of 1918–1919, or Wielkopolska uprising of 1918–1919 (Polish: powstanie wielkopolskie 1918–1919 roku; German: Großpolnischer Aufstand) or Poznań War was a military insurrection of Poles in the Greater Poland region (German: Grand Duchy of Posen or Provinz Posen) against German rule. The uprising had a significant effect on the Treaty of Versailles, which granted a reconstituted Second Polish Republic the area won by the Polish insurrectionists. The region had been part of the Kingdom of Poland and then Polish–Lithuanian Commonwealth before the 1793 Second Partition of Poland when it was annexed by the German Kingdom of Prussia. It had also, following the 1806 Greater Poland uprising, been part of the Duchy of Warsaw (1807–1815), a French client state during the Napoleonic Wars.
Sources: en.wikipedia.org
Concerning females who have the condition congenital adrenal hyperplasia, the largest group requiring surgical genital correction, researcher Atilla Şenaylı stated, "The main expectations for the operations are to create a normal female anatomy, with minimal complications and improvement of life quality". Şenaylı added that "[c]osmesis, structural integrity, the coital capacity of the vagina, and absence of pain during sexual activity are the parameters to be judged by the surgeon". (Cosmesis usually refers to the surgical correction of a disfiguring defect.) He stated that although "expectations can be standardized within these few parameters, operative techniques have not yet become homogeneous. Investigators have preferred different operations for different ages of patients". Gender assessment and surgical treatment are the two main steps in intersex operations. "The first treatments for clitoromegaly were simply resection of the clitoris. Later, it was understood that the clitoris glans and sensory input are important to facilitate orgasm", stated Atilla. The clitoral glans' epithelium "has high cutaneous sensitivity, which is important in sexual responses", and it is because of this that "recession clitoroplasty was later devised as an alternative, but reduction clitoroplasty is the method currently performed".
Congenital myopathy is a very broad term for any muscle disorder present at birth. This defect primarily affects skeletal muscle fibres and causes muscular weakness and/or hypotonia. Congenital myopathies account for one of the top neuromuscular disorders in the world today, comprising approximately 6 in 100,000 live births every year. As a whole, congenital myopathies can be broadly classified as follows:
==== 2300–2399 ==== Sandwell Borough Council (Patent Shaft/Moorcroft Infrastructure) (Walsall Canal Bridge) Scheme 1993 Confirmation Instrument 1993 (S.I. 1993/2302) Civil Aviation (Canadian Navigation Services) (Fourth Amendment) Regulations 1993 (S.I. 1993/2320) Highlands and Islands Rural Enterprise Programme (Revocation) Regulations 1993 (S.I. 1993/2325) Value Added Tax (Reverse Charge) Order 1993 (S.I. 1993/2328) Telecommunications (Leased Lines) Regulations 1993 (S.I. 1993/2330) Coal Mines (Owner's Operating Rules) Regulations 1993 (S.I. 1993/2331) Combined Probation Areas (East Sussex) Order 1993 (S.I. 1993/2332) Plant Health Fees (Scotland) Amendment Order 1993 (S.I. 1993/2344) Environmentally Sensitive Areas (Cairngorms Straths) Designation Order 1993 (S.I. 1993/2345) Act of Sederunt (Enforcement of Judgments under the Civil Jurisdiction and Judgments Act 1982) (Authentic Instruments and Court Settlements) 1993 (S.I. 1993/2346) Haydon Natural Gas Pipe–lines Order 1993 (S.I. 1993/2347) Croydon, Merton and Sutton (London Borough Boundaries) Order 1993 (S.I. 1993/2350) Angola (United Nations Sanctions) Order 1993 (S.I. 1993/2355) Angola (United Nations Sanctions) (Dependent Territories) Order 1993 (S.I. 1993/2356) Angola (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/2357) Angola (United Nations Sanctions) (Isle of Man) Order 1993 (S.I. 1993/2358) Exempt Charities Order 1993 (S.I. 1993/2359) Clinical Thermometers (EEC Requirements) Regulations 1993 (S.I. 1993/2360) Ionising Radiations (Outside Workers) Regulations 1993 (S.I.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.